Intellect Neurosciences, Inc., a biopharmaceutical company, engages in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer’s disease and other disorders of the central nervous system. The company’s product pipeline includes small molecules, monoclonal antibodies, and vaccines that address unmet needs in Alzheimer’s disease and other indications, including ataxia, Parkinson’s disease, Huntington’s disease, diabetes, stroke, myelodysplastic syndromes, motor neuron disease (ALS and Lou Gehrig’s disease), and radiation injury. Its lead drug candidate, OXIGON, is a chemically synthesized form of a small, potent, dual mode of action, naturally occurring molecule with potential as a disease-modifying agent for Alzheimer’s disease and other therapeutic indications. OXIGON has completed human Phase Ia clinical trials. Intellect Neurosciences also develops immunotherapies (monoclonal antibodies and vaccines) to prevent or arrest the progression of Alzheimer’s disease, while avoiding the risk of adverse reactions. The company also has various proprietary immunotherapy platforms, such as ANTISENILIN, RECALL-VAX, and BETA-VAX with patented drug candidates for both passive and active immunization against Alzheimer’s disease. ANTISENILIN is a passive monoclonal antibody platform, and RECALL-VAX and BETA-VAX are platform technologies for vaccination.
ILNS at 10:42 AM 1/7/2009: Currently at 11x average daily volume.
Tags: OTC Bulletin Board, OTCBB, OTCBB Stocks
Leave a Reply
You must be logged in to post a comment.
